Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Foster, Graham R.; Pianko, Stephen; Brown, Ashley; Forton, Daniel; Nahass, Ronald; George, Jacob; Barnes, Eleanor; Brainard, Diana M.; Massetto, Benedetta; Lin, Ming‐Yen; Han, Bin; McHutchison, John G.; Subramanian, G. Mani; Cooper, Curtis; Agarwal, Kosh

doi:10.1053/j.gastro.2015.07.043

Cited by 229 publications

(287 citation statements)

References 13 publications

Supporting

Mentioning

250

Contrasting

Unclassified

Order By: Relevance

“…In a cohort of 32 treatment-experienced GT-2 cirrhotic patients, SVR rates were 87% (13/15) after 16 weeks of SOF/RBV therapy and 100% (17/17) after 24 weeks. 37 …”

Section: Genotypesmentioning

confidence: 99%

“…37 Treatment-naive genotype 3: The FISSION trial compared results of 12 weeks of SOF and RBV therapy with that of 24 weeks Peg-IFNa and RBV in treatment-naive HCV patients. The SVR in GT-3 patients was 53% with SOF and RBV therapy, which were much lower than that for GT-2 (SVR 97%).…”

Section: Genotypementioning

confidence: 99%

“…Rates of SVR12 among patients with GT-2 HCV were 87% and 100%, for those receiving 16 and 24 weeks of SOF/RBV, respectively, and 94% for those receiving SOF and Peg-IFNa/RBV for 12 weeks. 37 …”

Section: Genotypementioning

confidence: 99%

See 2 more Smart Citations

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

India contributes significantly to the global burden of HCV. While the nucleoside NS5B inhibitor sofosbuvir became available in the Indian market in March 2015, the other directly acting agents (DAAs), Ledipasvir and Daclatasvir, have only recently become available in the India. The introduction of these DAA in India at a relatively affordable price has led to great optimism about prospects of cure for these patients as not only will they provide higher efficacy, but combination DAAs as all-oral regimen will result in lower side effects than were seen with pegylated interferon alfa and ribavirin therapy. Availability of these newer DAAs has necessitated revision of INASL guidelines for the treatment of HCV published in 2015. Current considerations for the treatment of HCV in India include the poorer response of genotype 3, nonavailability of many of the DAAs recommended by other guidelines and the cost of therapy. The availability of combination DAA therapy has simplified therapy of HCV with decreased reliance of evaluation for monitoring viral kinetics or drug related side effects. ( J CLIN EXP HEPATOL 2016;6:119-145) T here have been revolutionary changes in the management of chronic hepatitis C (CH-C) over the last few years. Pegylated interferon alfa (Peg-IFNa) plus ribavirin (RBV) therapy, which till the recent past was the standard of care, has been eclipsed by the arrival of newer directly acting antiviral agents (DAAs). Not only do the DAAs have better efficacy, they are also associated with lower side effects, have better tolerability, a shorter duration of therapy, and have simpler administration.In the recent guidelines issued by the American Association for the study of Liver Diseases (AASLD), in collaboration with the Infectious Diseases Society of America 1 and the European Association for Study of the Liver z (EASL), 2 the role of Peg-IFNa/RBV therapy in the management of HCV has been relegated to second-line, backup status. These newer guidelines, however, cannot be implemented in India as many of the recommended drugs are yet to be marketed in India. Other considerations for the treatment of HCV in India are a predominance of

show abstract

“…In a cohort of 32 treatment-experienced GT-2 cirrhotic patients, SVR rates were 87% (13/15) after 16 weeks of SOF/RBV therapy and 100% (17/17) after 24 weeks. 37 …”

Section: Genotypesmentioning

confidence: 99%

Section: Genotypementioning

confidence: 99%

See 1 more Smart Citation

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Puri

Saraswat

Dhiman

et al. 2016

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

show abstract

“…Experience of different DAA combinations in the real world is growing within a number of compassionate use programs [5,7]. However, virological response with all oral DAAs in decompensated cirrhosis, particularly in HCV genotype 3, is lower than in patients with less advanced liver disease [8,9]. Remaining uncertainties in treating such patients include the optimal duration of therapy, whether or not the regimen should include ribavirin, and what, if any, clinical benefits accrue to patients with such advanced liver disease following clearance of virus.…”

Section: Introductionmentioning

confidence: 99%

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Foster

Irving

Cheung

et al. 2016

Journal of Hepatology

Self Cite

442

432

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…The reason for this is unknown, but could be explained by a distinct pattern of RAVs and an increase in the prevalence of “favorable” IFNL4 SNPs in this genotype. Here, we used a large cohort of 496 HCVg3a‐infected patients (from the BOSON clinical study2) and report no significant association ( P > 0.05) between the treatment‐beneficial C/C genotype of INFL4 and RAV site Y93H in the NS5A gene.…”

Section: Tablementioning

confidence: 99%

Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a

et al. 2016

Self Cite

View full text Add to dashboard Cite

Efficacy of Sofosbuvir Plus Ribavirin With or Without Peginterferon-Alfa in Patients With Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients With Cirrhosis and Hepatitis C Virus Genotype 2 Infection

Cited by 229 publications

References 13 publications

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016

Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis

Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a

Contact Info

Product

Resources

About